Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-21T02:26:14.342Z Has data issue: false hasContentIssue false
  • English
  • Français

P03-367 - Sertindole in the Treatment of Tardive Dyskinesia in a Patient with Genetically Abnormal Dopamine D3 Receptors

Published online by Cambridge University Press:  17 April 2020

E. Rizos ,
A. Douzenis ,
I. Michopoulos ,
N. Siafakas ,
E. Katsantoni ,
R. Gournellis  and
L. Lykouras
E. Rizos
Affiliation:
2nd Dpt of Psychiatry, ‘ATTIKON’ General Hospital, Medical School, University of Athens, Greece
A. Douzenis
Affiliation:
2nd Dpt of Psychiatry, University of Athens, Greece
I. Michopoulos
Affiliation:
2nd Dpt of Psychiatry, University of Athens, Greece
N. Siafakas
Affiliation:
Laboratory of Clinical Microbiology, ‘ATTIKON’ General Hospital, Medical School, University of Athens, Greece
E. Katsantoni
Affiliation:
Hematology-Oncology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece
R. Gournellis
Affiliation:
2nd Dpt of Psychiatry, ‘ATTIKON’ General Hospital, Medical School, University of Athens, Greece
L. Lykouras
Affiliation:
2nd Dpt of Psychiatry, ‘ATTIKON’ General Hospital, Medical School, University of Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

Tardive dyskinesia (TD) is a difficult-to-treat condition. The presence of genetically abnormal D2 and D3 dopamine receptors is associated with increased like hood of TD in patients with schizophrenia. We present a case of a patient with TD and genetically abnormal dopamine D3 receptors with chronic schizophrenia, treated successfully by sertindole.

Methods

A 47-year old male with history of chronic chizophrenia was assessed clinically by means of SCID IV, PANSS and AIMS, and was genotyped for DRD3ser-gly and 5-HT2C receptor gene polymorphisms.

Results

The patient suffered from an exacerbation of positive and negative psychotic symptoms and TD. He was also found to be DRD3ser-gly heterozygous. He had been suffering from TD for two years, developed by chronic administration of haloperidole and resperidone. A trial with quetiapine failed to ameliorate his TD and psychotic symptoms, whereas a successive trial with clozapine induced life-treating hematological side effects. After the administration of sertindole (16mh/day) his psychotic and TD symptoms remitted (PANSS:29, AIMS : 0). One year later his level of improvement was wholly preserved.

Conclusion

Sertindole might be beneficial for the treatment of TD in patients who have genetically abnormal D3 receptors.

Type
Psychopharmacological treatment and biological therapies
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E973
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.